Open AccessConvalescent Plasma Therapy: The Early Use in Moderate to Severe COVID-19 Patients in Hospitals with Limited Resources
Author(s) -
Bagus Aulia Mahdi,
Satriyo Dwi Suryantoro,
Pradana Zaky Romadhon,
Choirina Windradi,
Krisniurul Widiyastuti,
Dwiki Novendrianto,
Etha Dini Widiasi,
Esthiningrum Dewi Agustin,
Sarah Firdausa,
Firas Farisi Alkaff
Publication year - 2021
Publication title -
indonesian journal of tropical and infectious disease/indonesian journal of tropical an infectious disease
Language(s) - English
Resource type - Journals
eISSN - 2356-0991
pISSN - 2085-1103
DOI - 10.20473/ijtid.v9i3.29113
Subject(s) - convalescent plasma , medicine , covid-19 , weakness , convalescence , pediatrics , intensive care medicine , emergency medicine , surgery , disease , infectious disease (medical specialty)
COVID-19 cases in Indonesia in the period of June-July 2021 showed a catastrophic spike. During this period, a recently discovered variant, the delta variant, appeared to be one of the sources of COVID-19 infection. Treatment modalities are limited due to reduced stock of drugs. A case of a 63-year-old man has been reported, with a history of having been vaccinated with two doses of Sinovac, experiencing moderate-to-severe symptoms of COVID-19 infection then given convalescent plasma therapy since his initial admission to the hospital. Three days after being given convalescent plasma therapy, the improvement was noticeable. Shortness of breath, cough, fever, and weakness were less complained. On the seventh day the patient fully recovered and got discharged. Convalescent plasma therapy was e ective in early stage and was able to improve outcomes. Indonesia needs sucient stocks of convalescent plasma as a therapy to overcome the limitations of medicines.